



June 6, 2025

JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website

- A refreshed global brand signals JCR's expanded international presence and unwavering focus on rare and genetic diseases worldwide -

Hyogo, Japan – June 6, 2025 – [JCR Pharmaceuticals Co., Ltd.](https://www.jcrpharm.com/) (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a [unique website](https://www.jcrpharm.com/) tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide.

“At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world,” said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. “In September, we celebrate the 50th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases.”

The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR’s commitment to bridge the gap between complex science and unmet needs of patients and families.

For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR’s [pipeline](https://www.jcrpharm.com/pipeline), beginning with lysosomal storage disorders (LSDs), and it reflects the company’s ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global [research, development, and manufacturing capabilities](https://www.jcrpharm.com/research-development-and-manufacturing-capabilities), with a focus on addressing unmet medical needs and expanding therapeutic possibilities.

Learn more about JCR, its technologies, and clinical development programs on its global website: <https://jcrpharm.com/>.

About the J-Brain Cargo® Platform Technology

JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO® (INN: pabinafusp alfa).

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that

develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website: <https://jcrpharm.com/>.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###